Urgent Updates | June 29

Cases of RSV in Older Adults Likely Underestimated in Studies

A review published in Infectious Diseases and Therapy found that studies are likely to underestimate the number of infections of respiratory syncytial virus (RSV) in older adults. The researchers concluded that infection of RSV was likely unreported or underestimated in older adults. However, it is unclear what the effect size of this underestimation is overall. This underestimation could underestimate the health benefits that can be gained through future medication and vaccines. Full Access: AJMC


ARS Pharmaceuticals Announces PDUFA Date Extension for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis

On June 20th, it was announced that the U.S. Food and Drug Administration (FDA) extended the Prescription Drug User Fee Act (PDUFA) target action date by three months (September 19, 2023) for the New Drug Application for neffy  (Intranasal (IN) Epinephrine) for the treatment of allergic reactions (Type 1), including anaphylaxis, for adults and children ≥30 kg. Full Access: FARE


Children’s Mental Health Represents National Emergency

An estimated one in five children in the U.S. experience a mental health disorder each year and as of 2021 suicide was the second leading cause of death among children aged 10-14, according to the Centers for Disease Control and Prevention. AMA to join with other interested parties to advocate for efforts to increase the mental health workforce to address the increasing shortfall in access to appropriate mental health care for children. Full Access: AMA


Development and Evaluation of an Integrated Outpatient Infusion Care Model for the Treatment of Pediatric Headache

Care for pediatric patients with headache often occurs in high-cost settings such as emergency department and inpatient settings. Outpatient infusion centers have the potential to reduce care costs for pediatric headache management. By developing an integrated ambulatory care model with infusion capacity for refractory pediatric headache is feasible, and this study early outcomes suggest this may have a favorable impact on the overall value of care for this population. Full Access: Pediatric Neurology